Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s):  XRTX

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance... see more

TSXV:XRTX - Post Discussion

XORTX Therapeutics Inc > 2022 promises to be a progressive year for therapeutic psych
View:
Post by partystocker on Feb 14, 2022 3:46pm

2022 promises to be a progressive year for therapeutic psych

2022 promises to be a progressive year for therapeutic psychedelics companies like Origin Therapeutics $ORIG


2021 was a milestone year for psychedelic therapy, and 2022 promises to be even more progressive in North America, with Canada kicking off the new year on a high note.


Health Canada will allow physicians to request patient access to illegal psychoactive substances, like MDMA and psilocybin, for psychedelic-assisted therapy. Decisions will remain on a case-by-case basis and will be reserved for serious treatment-resistant or life-threatening conditions, in instances where other therapies have failed, are unsuitable or are not available in Canada. This amendment is a reversal of a 2013 Health Canada policy that prevented “a letter of authorization for a new drug that is or that contains a restricted drug.”


This is a huge step forward for the industry and highlights the increasing value of companies like Origin Therapeutics.  


Origin is expected to go public on the CSE this year under the ticker $ORIG. With regulations continuing to trend towards the normalization of these novel therapies, the therapeutic psychedelic industry should start to see an acceleration in growth. 


https://psychedelicspotlight.com/health-canada-psychedelic-therapy-special-access-programme-amendment/#:~:text=Health%20Canada%20Grants%20Special%20Access%20to%20Restricted%20Drugs%20for%20Psychedelic%20Therapy&text=New%20amendment%20reverses%20a%202013,that%20contains%20a%20restricted%20drug.%22
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities